Alduais Y et al (2023) Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment. Medicine (Baltimore) 102(8):e32899

Article  CAS  PubMed  Google Scholar 

Chen Y, Wang X (2020) miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res 48(D1):D127-d131

Article  CAS  PubMed  Google Scholar 

Chen Y et al (2021) Long non-coding RNAs: from disease code to drug role. Acta Pharm Sin B 11(2):340–354

Article  CAS  PubMed  Google Scholar 

Deng SH et al (2021) miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549. Biochem Biophys Res Commun 549:54–60

Article  CAS  PubMed  Google Scholar 

Deng Q et al (2020) Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer. Aging (Albany NY) 12(9): 8001–8015.

Fan C et al (2020) Long non-coding RNA MALAT1 regulates oxaliplatin-resistance via miR-324-3p/ADAM17 axis in colorectal cancer cells. Cancer Cell Int 20:473

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu K et al (2022) Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol 15(1):173

Article  PubMed  PubMed Central  Google Scholar 

Győrffy B (2024) Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation (Camb) 5(3):100625

PubMed  Google Scholar 

He W et al (2024) DUSP1 Promotes Osimertinib drug-tolerant persistence by inhibiting MAPK/ERK signaling in non-small cell lung cancer. Mol Biotechnol, 2024.

Hisakane K et al (2021) Exosome-derived miR-210 involved in resistance to osimertinib and epithelial-mesenchymal transition in EGFR mutant non-small cell lung cancer cells. Thorac Cancer 12(11):1690–1698

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong DS et al (2020) Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer 122(11):1630–1637

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang WJ et al (2020) The β-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis. Oncogene 39(23):4538–4550

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang X et al (2021) Silencing of CASC8 inhibits non-small cell lung cancer cells function and promotes sensitivity to osimertinib via FOXM1. J Cancer 12(2):387–396

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kryczka J et al.(2021) Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy. Int J Mol Sci 22(16).

Li JH et al (2014) starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 42(Database issue):D92–7.

Lin MH et al (2018) Comprehensive identification of microRNA arm selection preference in lung cancer: miR-324-5p and -3p serve oncogenic functions in lung cancer. Oncol Lett 15(6):9818–9826

PubMed  PubMed Central  Google Scholar 

Malapelle U et al (2018) Osimertinib. Recent Results Cancer Res 211:257–276

Article  CAS  PubMed  Google Scholar 

McCabe EM, Rasmussen TP (2021) lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions. Semin Cancer Biol 75:38–48

Article  CAS  PubMed  Google Scholar 

Nakano Y et al (2023) Upregulation of long non-coding RNA LINC00460 in EGFR-mutant lung cancer indicates a poor prognosis in patients treated with osimertinib. Oncol Lett 26(3):380

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishiyama A et al (2020) MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. Cancer Sci 111(10):3813–3823

Article  CAS  PubMed  PubMed Central  Google Scholar 

Planchard D et al (2015) EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol 26(10):2073–2078

Article  CAS  PubMed  Google Scholar 

Ramalingam SS et al (2018) Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol 36(9):841–849

Article  CAS  PubMed  Google Scholar 

Rebuzzi SE et al (2020) Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives. Crit Rev Oncol Hematol 146:102820

Article  PubMed  Google Scholar 

Shaikh M et al (2022) Emerging approaches to overcome acquired drug resistance obstacles to osimertinib in non-small-cell lung cancer. J Med Chem 65(2):1008–1046

Article  CAS  PubMed  Google Scholar 

Shi L et al (2022) Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer. Clin Transl Med 12(7):e989

Article  CAS  PubMed  PubMed Central  Google Scholar 

Si J et al (2021) HIF1A-AS2 induces osimertinib resistance in lung adenocarcinoma patients by regulating the miR-146b-5p/IL-6/STAT3 axis. Mol Ther Nucleic Acids 26:613–624

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taghvimi S et al (2022) LncRNAs roles in chemoresistance of cancer cells. Curr Mol Med 22(8):691–702

Article  CAS  PubMed  Google Scholar 

Takahashi S et al (2021) Long non-coding RNA CRNDE is involved in resistance to EGFR tyrosine kinase inhibitor in EGFR-mutant lung cancer via eIF4A3/MUC1/EGFR signaling. Int J Mol Sci 22(8).

Tang YF et al (2024) circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p/ IGF1R pathway in non-small cell lung cancer (NSCLC). Mol Cancer 23(1):91

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Zandwijk N et al (2017) Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol 18(10):1386–1396

Article  PubMed  Google Scholar 

Wang L, Li M, Lian R (2022) Depleting hsa_circ_0000567 suppresses acquired gefitinib resistance and proliferation of lung adenocarcinoma cells through regulating the miR-377-3p / ZFX axis: an in vitro and in vivo study. Histol Histopathol 37(7):637–654

CAS  PubMed  Google Scholar 

Wang N et al (2023) Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer. Mol Omics 19(3):238–251

Article  CAS  PubMed  Google Scholar 

Wang Z et al (2024) LncRNA LINC01278 regulates the prognosis and related mechanisms of gastric cancer by targeting miR-129-5p. J Environ Pathol Toxicol Oncol 43(4):43–52

Article  PubMed  Google Scholar 

Wéber A et al (2023) Lung cancer mortality in the wake of the changing smoking epidemic: a descriptive study of the global burden in 2020 and 2040. BMJ Open 13(5):e065303

Article  PubMed  PubMed Central  Google Scholar 

Winkle M et al (2021) Noncoding RNA therapeutics—challenges and potential solutions. Nat Rev Drug Discov 20(8):629–651

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu J et al (2021a) LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma. Biomark Res 9(1):9

Article